Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.54 |
| ▸ | GNRHR | P30968 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391085 | 0.92 | RXRA (0.54) | RXRANR1H2NR1H3GNRHRMAPK14 | |
| SCHEMBL2388042 | 0.92 | RXRA (0.59) | RXRANR1H2NR1H3GNRHRMAPK14 | |
| SCHEMBL2389316 | 0.91 | RXRA (0.55) | RXRANR1H2NR1H3MAPK14HTR2A | |
| SCHEMBL2387813 | 0.90 | RXRA (0.51) | RXRANR1H2NR1H3GNRHRHTR2A | |
| SCHEMBL2390903 | 0.90 | RXRA (0.65) | RXRANR1H2NR1H3GNRHRMAPK14 | |
| SCHEMBL2387648 | 0.87 | RXRA (0.58) | RXRANR1H2NR1H3 | |
| SCHEMBL2388370 | 0.86 | RXRA (0.53) | RXRANR1H2NR1H3GNRHRMAPK14 | |
| SCHEMBL2386672 | 0.86 | RXRA (0.60) | RXRANR1H2NR1H3MAPK14 | |
| SCHEMBL2387488 | 0.86 | RXRA (0.66) | RXRANR1H2NR1H3MAPK14 | |
| SCHEMBL2387650 | 0.84 | RXRA (0.58) | RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | claimed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | RXRA 16/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | RXRA 16/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.